MENTHO PATCH COOL Label Puts OTC Menthol Therapy in Clear Relief
DailyMed’s current label for MENTHO PATCH COOL defines a topical over-the-counter analgesic intended for the temporary relief of minor aches and pains of muscles and joints tied to simple backache, arthritis, strains, and sprains. The product sits squarely in the familiar counterirritant category, where topical cooling and sensory distraction are used to blunt the perception of pain rather than to modify the underlying musculoskeletal condition itself. For clinicians and pharmacists, the label is a reminder that these products are designed for symptom control only, and their role is narrow by design.
The active ingredient is menthol, listed at 15 mg in 1 g, with camphor and methyl salicylate also named among the active ingredients in the label body. That combination is consistent with a classic topical analgesic approach: menthol produces a cooling sensation and counterirritant effect, camphor contributes local sensory stimulation, and methyl salicylate is commonly used in rubefacient-style pain products. The physiologic logic is local and superficial, relying on cutaneous sensory pathways rather than systemic exposure. For patients with focal muscular discomfort, that can translate into a short-term, noninvasive option when oral analgesics are undesirable or unnecessary.
The product is packaged as a human OTC drug in topical form, with NDC 72602-002-01 and a single 10 g patch presentation. Marketing began on September 20, 2018, and the current label is marked as updated October 6, 2026. The manufacturer and labeler is THE EGYPTIAN SAUDI CO FOR MEDICAL MANUFACTURING MASCOMID. In practical terms, the label reflects a conventional consumer analgesic positioned for external use rather than a prescription pathway or a monitored inpatient setting.
Directions and Use Limits Define the Safety Envelope
The directions are straightforward: adults and children 3 years of age and older should apply the patch to the affected area not more than 3 to 4 times daily. Children under 3 years of age should consult a doctor. That age cutoff matters because younger children are more vulnerable to dosing errors, accidental ingestion, and inadvertent overexposure to topical analgesic ingredients. With OTC pain products, the visible packaging can invite casual use; the label places a firm boundary on frequency and pediatric self-treatment.
A single sentence captures the key clinical caution: MENTHO PATCH COOL is for external use only.
The warnings are direct and clinically familiar. Avoid contact with the eyes. Do not apply to open wounds or damaged skin. Do not bandage tightly. These restrictions are not cosmetic language; they address the routes by which topical irritants can become more than a local nuisance. Occlusion can increase absorption and intensify irritation, while compromised skin can permit deeper penetration of topical agents. Eye exposure is especially problematic because menthol-containing products can trigger marked discomfort and reflex tearing even at small amounts.
Ingredient Profile Points to a Conventional Counterirritant Patch
The inactive ingredient list is extensive and includes glycerin, sodium polyacrylate, aluminum chloride anhydrous, citric acid monohydrate, tartaric acid, polysorbate 80, isopropyl myristate, carboxymethylcellulose sodium, edetate disodium, polyacrylic acid, titanium dioxide, water, and carbomer copolymer type B. This kind of formulation supports adhesion, stability, texture, moisture handling, and controlled topical application. The chemistry of the patch matters because a topical analgesic is only as useful as its ability to remain in place, deliver the active ingredients consistently, and avoid unnecessary skin trauma.
Patch-based delivery also changes the bedside conversation. Patients often think of a patch as gentler than a cream or ointment, and in many cases that is true from a handling standpoint. Yet patch design can also encourage prolonged skin contact and inadvertent overuse if the product is applied repeatedly without attention to the label limits. The warning against tight bandaging acknowledges the same issue from another angle: more occlusion is not automatically better, particularly with irritant-counterirritant products.
The label’s stop-use language is equally specific. Use should be discontinued and a doctor consulted if the condition worsens, if symptoms persist more than 7 days, or if symptoms clear up and then recur within a few days. Those triggers help separate transient minor pain from a pattern that could reflect a more serious musculoskeletal, inflammatory, or traumatic problem. Persistent backache, recurrent joint pain, or worsening strain can require evaluation beyond topical symptom relief, especially when function declines or swelling, warmth, fever, or neurologic symptoms enter the picture.
Storage and Poison-Prevention Language Reflect Real-World Risk
Storage instructions call for a cool, dry place away from direct sunlight. That is standard product handling language, but it also speaks to the stability demands of topical formulations built around adhesive and moisture-sensitive components. Heat and sunlight can degrade both the physical integrity of the patch and the consistency of drug delivery.
The label’s child safety warning is concise and urgent: keep out of reach of children. If swallowed, seek medical help or contact a Poison Control Center right away. That instruction is particularly important for products containing menthol, camphor, and methyl salicylate, all of which can become hazardous if ingested. In outpatient care, accidental pediatric exposure is one of the most important risks attached to OTC topical pain products because the packaging can appear benign while the ingredients are pharmacologically active.
DailyMed also lists the product under OTC monograph drug category M017, reinforcing that this is an established nonprescription topical analgesic rather than a novel therapy or a new molecular entity. For clinicians, the label is less about innovation than about precision: who may use it, where it may be applied, how often it may be used, and when use should stop. Those details define the boundary between routine self-care and a situation that needs clinical reassessment.
The current label does not present comparative trial data, systemic efficacy endpoints, or safety outcomes beyond the standard external-use warnings. Its value is regulatory and practical rather than experimental. In that setting, the most clinically relevant issue is not whether the patch is dramatic, but whether it is used exactly as labeled and not mistaken for a solution to persistent or escalating pain.